Substance Use Disorders in Older Adults: Emerging Clinical Perspectives

Abstract

Substance use disorders (SUDs) in older adults represent an increasingly recognized public health concern, with significant implications for morbidity and mortality in the geriatric population. This review summarizes current evidence regarding epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of SUDs among older adults, integrating recent advances and emerging therapies. The article highlights the unique clinical challenges posed by aging biology, polypharmacy, comorbidities, and the need for age-adapted, guideline-based approaches to optimize outcomes in this vulnerable demographic.

Introduction

The global demographic shift toward an aging population has resulted in a parallel increase in the prevalence and clinical relevance of substance use disorders (SUDs) among older adults. Historically under-recognized, SUDs in this group are now acknowledged as a critical aspect of geriatric mental health, intersecting with age-related physiological changes, comorbidities, and social determinants. This review provides a comprehensive analysis of substance use disorders in older adults, with a focus on recent clinical perspectives and evidence-based management strategies for physicians and healthcare professionals.

Epidemiology / Disease Burden

The epidemiology of SUDs in older adults is complex and evolving. Recent epidemiological data indicate rising rates of alcohol, prescription drug, and illicit substance misuse among individuals aged 65 and older. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), the proportion of older adults with SUDs is projected to double between 2020 and 2030. Alcohol remains the most commonly misused substance, but there is increasing concern regarding prescription opioid and benzodiazepine misuse, often related to chronic pain and insomnia. The disease burden includes heightened risks of falls, cognitive impairment, multi-morbidity, hospitalizations, and premature mortality, imposing significant challenges on healthcare systems.

Pathophysiology

The pathophysiology of SUDs in older adults is influenced by age-related neurobiological and pharmacokinetic changes. There is reduced hepatic and renal clearance, altered body composition (increased fat-to-lean mass ratio), and changes in the blood-brain barrier, all of which amplify drug sensitivity and toxicity. Neuroplasticity declines with age, affecting reward circuitry and stress response, which may modify substance craving and withdrawal syndromes. Chronic substance use further exacerbates neurodegeneration and impairs organ function, accelerating frailty and cognitive decline in this population.

Risk Factors

Risk factors for SUDs in older adults are multifactorial, encompassing biological, psychological, and social domains. Key factors include chronic pain, polypharmacy, psychiatric comorbidities (depression, anxiety), bereavement, isolation, retirement, and reduced social support. Genetic predisposition and a history of substance misuse earlier in life also increase vulnerability. Furthermore, age-related sensory and functional decline can lead to maladaptive coping strategies, increasing substance use risk. Societal stigma and diagnostic overshadowing often delay recognition and intervention in this group.

Clinical Features

Clinical presentation of SUDs in older adults is often subtle and atypical, complicating timely diagnosis. Symptoms may include unexplained cognitive impairment, mood disturbances, falls, sleep disorders, and worsening of chronic medical conditions. Physical findings such as weight loss, poor hygiene, and dehydration may be present, while behavioral changes like social withdrawal or medication misuse often go unnoticed. The overlap with normal aging and comorbid diseases necessitates a high index of suspicion among clinicians.

Diagnosis

Diagnosis of SUDs in older adults requires a comprehensive, multidisciplinary approach. Standardized screening tools such as the Alcohol Use Disorders Identification Test (AUDIT) and the Drug Abuse Screening Test (DAST) can be adapted for geriatric populations. Collateral information from caregivers and family is invaluable. Laboratory assessments, including liver and renal function tests, medication reconciliation, and toxicology screens, are essential. Diagnostic criteria should consider age-related changes in presentation, and clinicians must differentiate SUDs from delirium, dementia, and depression, which commonly coexist or mimic substance-related symptoms.

Treatment & Management

Management of SUDs in older adults is challenging due to polypharmacy, comorbidities, and age-related vulnerabilities. Integrated care models, involving primary care, psychiatry, geriatric medicine, and social work, are recommended. Non-pharmacological interventions such as cognitive-behavioral therapy (CBT), motivational interviewing, and contingency management are effective and well-tolerated. Pharmacotherapy should be cautiously considered, with careful monitoring for adverse effects and drug interactions. Medications such as naltrexone and acamprosate for alcohol use disorder, and buprenorphine for opioid use disorder, may be utilized with age-appropriate dose adjustments. Supportive interventions addressing social isolation and functional decline are critical for sustained recovery.

Recent Advances / Emerging Therapies

Recent advances include the development of age-specific screening tools and tailored behavioral interventions. Technology-assisted care, such as telehealth and digital cognitive remediation, has shown promise in improving access and adherence among older adults. Emerging pharmacotherapies focus on minimizing cognitive side effects and improving tolerability. There is growing interest in interventions targeting neuroinflammation and neuroprotection, as well as the role of personalized medicine based on pharmacogenomics. Ongoing clinical trials are evaluating novel agents and integrated care pathways tailored to geriatric needs.

Guideline Recommendations

Guidelines from organizations such as the American Geriatrics Society and SAMHSA advocate for routine screening of SUDs in older adults, age-appropriate assessment tools, and multidisciplinary management approaches. They emphasize the importance of minimizing polypharmacy, regularly reviewing medication regimens, and prioritizing non-pharmacological therapies. Guidelines highlight the need for clinician education to improve detection and reduce stigma, and for greater integration between addiction medicine and geriatric care services to optimize outcomes in this population.

Conclusion

Substance use disorders in older adults are an underappreciated but growing challenge in clinical practice, demanding heightened awareness, systematic screening, and individualized management. Advances in research and clinical care are improving our understanding and ability to address SUDs in this demographic, yet significant gaps remain. Multidisciplinary, guideline-driven approaches are essential to mitigate morbidity and mortality, enhance quality of life, and support healthy aging in affected individuals.